The invention relates to a method of treating at least one symptom of lower urinary tract disease in a subject in need of treatment comprising administering to said subject a combination of an alpha<；SUB>；2<；/SUB>；delta calcium channel subunit (A2d) ligand and a non-steroidal anti-inflammatory drug (NSAID), wherein the administered amounts of A2d ligand and NSAID together comprise a therapeutically effective amount of an active combination of agents. The combination of A2d ligand and NSAID can result in a synergistic therapeutic effect, wherein the combined effect is greater than the additive effect resulting from separate, single administration of A2d ligand or NSAID. Combination of A2d ligand and NSAID is particularly useful in treatment of lower urinary tract disease which manifests symptoms of urinary incontinence.KOMBINOVANA TERAPIJA LIGANADA α2δ I NSAID ZA POREMEĆAJE DONjEG URINARNOG TRAKTA. Ligand podjedinice α2δ kalcijumovog kanala (A2d) koji se bira iz grupe koju čine:gabapentin, pregabalin, (1R,5R,6S)-6-aminometil-6-karboksimetil-biciklo[3.2.0]heptan, 3-(1-aminometilcikloheksilmetil)-4H-1,2,4-oksadiazol-5-on, 5-(1-aminometil- cikloheksilmetil)-1H-tetrazol, (3S,4S)-(1-aminometil-1-karboksimetil-3,4-dimetil- ciklopentan, (1α,3α,5α)-(3-aminometil-3-karboksimetil-biciklo[3.2.0]heptan, (3S,5R)-3-aminometil-5-metiloktanska kiselina, (3S,5R)-3-amino-5-metil-heptanska kiselina, (3S,5R)-3-amino-5-metiloktanska kiselina, (3S,5R)-3-amino-5-metilnonanska kiselina, (2S,4S)-4-(3-hlorofenoksi)-prolin ili (2S,4S)-4-(3-fluorobenzil)-prolin, ili smeša dva ili više navedenih, za upotrebu u tretmanu urinarne inkontinencije kod subjekta koji pati od nekog poremećaja donjeg urinarnog trakta, u kombinaciji sa prethodno, istovremeno ili naknadno ordiniraniranim nesteroidnim anti-inflamatornim lekom (NSAID).Prijava sadrži još 10 patentnih zahteva.
